Periera-Simon, SimoneXia, XiaomeiCatanuto, PaolaCoronado, RamonKurtzberg, JoanneBellio, MichaelLee, Yee-ShuanKhan, AishaSmith, RobinElliot, Sharon JGlassberg, Marilyn K2022-03-252022-03-252021-021323-77991440-1843https://hdl.handle.net/10161/24724<h4>Background and objective</h4>IPF is a fatal and debilitating lung disorder increasing in incidence worldwide. To date, two approved treatments only slow disease progression, have multiple side effects and do not provide a cure. MSC have promising therapeutic potential as a cell-based therapy for many lung disorders based on the anti-fibrotic properties of the MSC.<h4>Methods</h4>Critical questions remain surrounding the optimal source, timing and efficacy of cell-based therapies. The present study examines the most effective sources of MSC. Human MSC were derived from adipose, WJ, chorionic membrane (CSC) and chorionic villi (CVC). MSC were injected into the ageing mouse model of BLM-induced lung fibrosis.<h4>Results</h4>All sources decreased Aschroft and hydroxyproline levels when injected into BLM-treated mice at day 10 with the exception of CSC cells that did not change hydroxyproline levels. There were also decreases in mRNA expression of α_v -integrin and TNFα in all sources except CSC. Only ASC- and WJ-derived cells reduced AKT and MMP-2 activation, while Cav-1 was increased by ASC treatment as previously reported. BLM-induced miR dysregulation of miR-29 and miR-199 was restored only by ASC treatment.<h4>Conclusion</h4>Our data suggest that sources of MSC may differ in the pathway(s) involved in repair.Mesenchymal Stem CellsAnimalsMice, Inbred C57BLHumansPulmonary FibrosisDisease Models, AnimalInflammationBleomycinMicroRNAsRNA, MessengerMesenchymal Stem Cell TransplantationTransplantation, HomologousGene Expression RegulationAdultMaleProto-Oncogene Proteins c-aktCaveolin 1Matrix Metalloproteinase 2BiomarkersJournal article2022-03-25